| Group | Variable | N | Mean | SD | Minimum | Q1 | Median | Q3 | IQR | Maximum |
|---|---|---|---|---|---|---|---|---|---|---|
| A | CysCeGFR | 74 | 80.31 | 27.77 | 17.65 | 64.15 | 81.93 | 103.04 | 38.89 | 125.18 |
| A | Difference | 74 | 13.04 | 9.32 | 3.04 | 6.93 | 8.38 | 17.52 | 10.59 | 47.64 |
| A | ScreGFR | 74 | 67.27 | 26.53 | 7.18 | 52.45 | 68.92 | 83.98 | 31.53 | 117.24 |
| B | CysCeGFR | 1193 | 46.36 | 23.54 | 4.92 | 27.02 | 42.11 | 62.11 | 35.09 | 122.56 |
| B | Difference | 1193 | -22.69 | 13.25 | -130.63 | -30.87 | -19.71 | -12.87 | 18.00 | -3.65 |
| B | ScreGFR | 1193 | 69.05 | 28.67 | 9.42 | 44.78 | 67.61 | 91.71 | 46.94 | 178.39 |
| Characteristic |
Group
|
p-value2 | |
|---|---|---|---|
| A N = 741 |
B N = 1,1931 |
||
| Gender | 0.408 | ||
| Female | 7 (9.5%) | 152 (12.7%) | |
| Male | 67 (90.5%) | 1,041 (87.3%) | |
| Missing / unrecognized | 0 | 0 | |
| Smoking | 0.077 | ||
| Never | 39 (52.7%) | 470 (39.5%) | |
| Former | 26 (35.1%) | 550 (46.2%) | |
| Current | 9 (12.2%) | 170 (14.3%) | |
| Missing / unrecognized | 0 | 3 | |
| BMI, mean (SD) | 34.3 (7.4) | 35.3 (9.0) | 0.283 |
| Missing / unrecognized | 0 | 1 | |
| Steroid | 0.071 | ||
| No | 74 (100.0%) | 1,138 (95.4%) | |
| Yes | 0 (0.0%) | 55 (4.6%) | |
| Missing / unrecognized | 0 | 0 | |
| Rheum Diseases | 0.622 | ||
| No | 3 (75.0%) | 76 (51.7%) | |
| Yes | 1 (25.0%) | 71 (48.3%) | |
| Missing / unrecognized | 70 | 1,046 | |
| Thyroid Disease | 0.033 | ||
| No | 64 (95.5%) | 980 (86.5%) | |
| Yes | 3 (4.5%) | 153 (13.5%) | |
| Missing / unrecognized | 7 | 60 | |
| Malignancy | 0.259 | ||
| No | 57 (85.1%) | 888 (79.4%) | |
| Yes | 10 (14.9%) | 231 (20.6%) | |
| Missing / unrecognized | 7 | 74 | |
| Liver Disease | 0.049 | ||
| No | 73 (98.6%) | 1,105 (92.6%) | |
| Yes | 1 (1.4%) | 88 (7.4%) | |
| Missing / unrecognized | 0 | 0 | |
| HIV | >0.999 | ||
| No | 74 (100.0%) | 1,188 (99.6%) | |
| Yes | 0 (0.0%) | 5 (0.4%) | |
| Missing / unrecognized | 0 | 0 | |
| Hyperlipidemia | <0.001 | ||
| No | 24 (32.4%) | 196 (16.4%) | |
| Yes | 50 (67.6%) | 997 (83.6%) | |
| Missing / unrecognized | 0 | 0 | |
| Hypertension | 0.001 | ||
| No | 20 (27.0%) | 161 (13.5%) | |
| Yes | 54 (73.0%) | 1,032 (86.5%) | |
| Missing / unrecognized | 0 | 0 | |
| DM2 | <0.001 | ||
| No | 46 (62.2%) | 473 (39.6%) | |
| Yes | 28 (37.8%) | 720 (60.4%) | |
| Missing / unrecognized | 0 | 0 | |
| 1 n (%); Mean (SD) | |||
| 2 Pearson’s Chi-squared test; Welch Two Sample t-test; Fisher’s exact test | |||
| Predictor | Adjusted OR | 95% CI | p-value |
|---|---|---|---|
| genderMale | 2.463 | 0.972 to 6.245 | 0.058 |
| SmokingFormer | 0.695 | 0.400 to 1.205 | 0.195 |
| SmokingCurrent | 0.558 | 0.248 to 1.257 | 0.159 |
| BMI | 0.963 | 0.934 to 0.992 | 0.014 |
| SteroidYes | 0.000 | 0.000 to Inf | 0.985 |
| Thyroid DiseaseYes | 0.360 | 0.110 to 1.179 | 0.091 |
| MalignancyYes | 0.768 | 0.374 to 1.577 | 0.473 |
| Liver DiseaseYes | 0.221 | 0.030 to 1.643 | 0.140 |
| HIVYes | 0.000 | 0.000 to Inf | 0.995 |
| HyperlipidemiaYes | 0.535 | 0.285 to 1.005 | 0.052 |
| HypertensionYes | 0.685 | 0.349 to 1.346 | 0.272 |
| DM2Yes | 0.489 | 0.277 to 0.862 | 0.013 |
Model N = 1183 (A: 67; B: 1116). Excluded for missing predictors: 84.
Table notes: Group A: CysCeGFR > ScreGFR; Group B: CysCeGFR < ScreGFR. Difference = CysCeGFR − ScreGFR. The default selects each patient’s latest valid paired laboratory record, dated by the later of the two laboratory timestamps. Equal eGFR values are excluded. Categorical percentages use nonmissing group denominators. BMI is mean (SD). Comparison p-values use Welch’s t-test for BMI and chi-square or Fisher’s exact tests for categorical characteristics. Logistic outcome: A = 1, B = 0; 11 characteristics are candidate predictors; Rheum Diseases is excluded from the regression and its complete-case check. Reference levels are Female, Never smoking, and No where present. Odds ratios are adjusted for the other estimable predictors; confidence intervals are Wald 95% intervals. Missing/unknown values remain missing. P-values are unadjusted.